A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a ...

GALWAY, Ireland--(BUSINESS WIRE)--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive data from 21 patients treated ...

A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern ...

Windtree Therapeutics, Inc. announced the issuance of a new patent for istaroxime, an intravenous formulation aimed at treating acute heart failure (AHF), a condition responsible for 1.3 million ...

The drugs currently available, which are used for acute decompensated heart failure treatment in intensive care, temporarily increase cardiac output but can have profound negative effects on the heart ...

Patients with therapeutic intensification of pharmacological pressure-unloading therapy had marked improvements in cardiac load, the study found, as demonstrated by reductions in N-terminal pro-B-type ...

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...

Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...

ZURICH, March 22 (Reuters) - Novartis said on Wednesday its serelaxin drug for patients with acute heart failure had failed a global phase III trial which tested its ability to reduce deaths from the ...

A multicenter study has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death. A multicenter study led by Vanderbilt University Medical Center ...